2021

presented by
BioPharma, Pharma

Heart drug’s trial failure busts bid to best Pfizer, but BridgeBio still bets on coming data

BridgeBio reported its drug acoramidis missed the main goal of a pivotal study in patients with transthyretin amyloidosis affecting the heart—the same type of patients helped by a currently approved blockbuster Pfizer drug. BridgeBio attributed the trial failure to a surprisingly strong placebo response, and it will continue the study, hoping for better outcomes on additional goals.